ARIAD’s proprietary portfolio of cell-signaling regulation technologies includes the ARGENT signaling and transcription technologies. Our ARGENT technologies allow intracellular processes to be controlled with small molecules, which may be useful in the development of therapeutic vaccines and gene and cell therapy products, and which provide versatile tools for applications in cell biology, functional genomics and drug-discovery research, including three-hybrid screening approaches to discover and characterize targets and lead molecules.
We distribute our ARGENT technologies at no cost to academic investigators in the form of our Regulation Kits. We have entered into more than 1,300 material transfer agreements with more than 500 different institutions in 33 countries for the use of this technology in diverse areas of research, and more than 300 scientific papers describing their use have been published. In addition, we have licensed the ARGENT technology to several pharmaceutical and biotechnology companies for research and development and/or commercial purposes.
For more information, please refer to the Regulation Kits section of our website.
For more information about partnering and licensing opportunities with ARIAD, please contact: Richard W. Pascoe at rich.pascoe@ariad.com or (617) 494-0400.
